CARDIOGENESIS

Cardiogenesis designs, develops, and distributes innovative devices for the treatment of chronic cardiac ischemia. The company’s market leading transmyocardial revascularization (TMR) technology platform utilizes a holmium:YAG laser energy source delivered through a range of minimally invasive fiberoptic delivery systems.

Published long term results demonstrate the efficacy of the TMR treatment in patients suffering from severe refractory angina, when stenting or bypass surgery is no longer an option. The company is building on the TMR platform in combining laser treatment with the delivery of autologous cell therapy in a single delivery system. This PHOENIX combination delivery system is CE Mark approved and has been submitted under an IDE application to the FDA.

Cardiogenesis sells its products primarily to hospitals in the United States through a direct sales and support organization, as well as through distributors and agents in North America and Europe.

Transmyocardial revascularization is performed with a low powered Holmium:YAG laser that delivers precise laser energy directly to the target area(s) of the heart muscle. When performed as a sole therapy, it is done through a small incision between the ribs (thoracotomy) with the patient under general anesthesia. TMR can also be performed as a complement to bypass surgery in patients that have diseased areas of the heart that cannot be bypassed. The precise laser energy is delivered to create small channels into the heart chamber.

Transmyocardial Revascularization is recommended by the American College of Cardiology / American Heart Association, the Society of Thoracic Surgeons, and the International Society of Minimally Invasive Cardiothoracic Surgeons, and reimbursed as a primary treatment and as a secondary treatment to coronary artery bypass grafting.

The One Year Maintenance and Full Service Warranty Program includes: two scheduled system calibration and maintenance actions; no charge parts replacement and repair labor; rapid emergency response; any and all costs associated with maintaining the Cardiogenesis holmium: YAG TMR system within manufacturer’s specifications as required due to normal and reasonable operation and handling of the system. Pricing valid for for continental USA only.

Cardiogenesis Corporation is a cardiovascular device company innovating new treatments for cardiovascular disease and a leader in therapies designed to stimulate cardiac angiogenesis (new blood vessel formation) and aid in revascularization of patients with ischemic heart disease. The company’s market leading holmium:YAG laser and fiber optic delivery systems are used to treat patients suffering from the debilitating pain of severe angina.